Evidence map›Paper›PMID 34469549›Full record

ArticleThe Journal of infectious diseases2021

Modeling Optimal Laboratory Testing Strategies for Bacterial Meningitis Surveillance in Africa.

Joseph Walker, Heidi M Soeters, Ryan Novak, Alpha Oumar Diallo, Jeni Vuong, Brice Wilfried Bicaba, Isaie Medah, Issaka Yaméogo, Rasmata Ouédraogo-Traoré, Kadidja Gamougame and 19 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 12 institutions in 8 countries.

Joseph WalkerDepartment of Epidemiology, College of Public Health, University of Georgia, Athens, Georgia, USA.
Heidi M SoetersDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ryan NovakDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Alpha Oumar DialloDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jeni VuongDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Brice Wilfried BicabaDirection de la Protection de la Santé de la Population, Ouagadougou, Burkina Faso.
Isaie MedahDirection de la Protection de la Santé de la Population, Ouagadougou, Burkina Faso.
Issaka YaméogoDirection de la Protection de la Santé de la Population, Ouagadougou, Burkina Faso.
Rasmata Ouédraogo-TraoréCentre Hospitalier Universitaire Pédiatrique Charles De Gaulle, Ouagadougou, Burkina Faso.
Kadidja GamougameMinistère de la Santé Publique du Tchad, N'Djamena, Tchad.
Daugla Doumagoum MotoSwiss Tropical and Public Health Institute, N'Djamena, Tchad.
Assétou Y DembéléDirection Nationale de la Santé, Bamako, Mali.
Ibrehima GuindoDirection Nationale de la Santé, Bamako, Mali.
Souleymane CoulibalyInstitut National de Recherche en Santé Publique, Bamako, Mali.
Djibo IssifouDirection de la Surveillance et Riposte aux Epidémies, Ministère de la Santé Publique, Niamey, Niger.
Maman ZaneidouDirection de la Surveillance et Riposte aux Epidémies, Ministère de la Santé Publique, Niamey, Niger.
Hamadi AssaneMinistère de la Santé et de l'Hygiène Publique, Lomé, Togo.
Christelle NikiemaMinistère de la Santé et de l'Hygiène Publique, Lomé, Togo.
Adodo SadjiInstitut National D'Hygiène, Lomé, Togo.
Katya FernandezWorld Health Organization Infectious Hazard Management, Geneva, Switzerland.
Jason M MwendaWorld Health Organization Regional Office for Africa, Brazzaville, Congo.
Andre BitaWorld Health Organization Inter-Country Support Team West Africa, Ouagadougou, Burkina Faso.
Clément LinganiWorld Health Organization Inter-Country Support Team West Africa, Ouagadougou, Burkina Faso.
Haoua TallAgence de Médecine Préventive, Ouagadougou, Burkina Faso.
Félix TarbangdoDavycas International, Ouagadougou, Burkina Faso.
Guetwende SawadogoDavycas International, Ouagadougou, Burkina Faso.
Marietou F PayeCenters for Disease Control and Prevention Foundation, Contracted to Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Xin WangDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Lucy A McNamaraDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-8240-7493
Centers for Disease Control and Prevention · USMinistère De La Santé · BFInternational Institute for Water and Environmental Engineering · BFMinistère de la Santé Publique · NETogolese Ministry of Health · TGCentre Hospitalier Universitaire Yalgado Ouédraogo · BFInstitut National de Recherche en Santé Publique · MLMinistère de la Santé · TNSwiss Tropical and Public Health Institute · CHUniversity of North Carolina at Chapel Hill · USWorld Health Organization · CHWorld Health Organization Regional Office for Africa · CG

Funding

World Health Organization 001
6 · The paper itself

Abstract

Since 2010, the introduction of an effective serogroup A meningococcal conjugate vaccine has led to the near-elimination of invasive Neisseria meningitidis serogroup A disease in Africa's meningitis belt. However, a significant burden of disease and epidemics due to other bacterial meningitis pathogens remain in the region. High-quality surveillance data with laboratory confirmation is important to monitor circulating bacterial meningitis pathogens and design appropriate interventions, but complete testing of all reported cases is often infeasible. Here, we use case-based surveillance data from 5 countries in the meningitis belt to determine how accurately estimates of the distribution of causative pathogens would represent the true distribution under different laboratory testing strategies. Detailed case-based surveillance data was collected by the MenAfriNet surveillance consortium in up to 3 seasons from participating districts in 5 countries. For each unique country-season pair, we simulated the accuracy of laboratory surveillance by repeatedly drawing subsets of tested cases and calculating the margin of error of the estimated proportion of cases caused by each pathogen (the greatest pathogen-specific absolute error in proportions between the subset and the full set of cases). Across the 12 country-season pairs analyzed, the 95% credible intervals around estimates of the proportion of cases caused by each pathogen had median widths of ±0.13, ±0.07, and ±0.05, respectively, when random samples of 25%, 50%, and 75% of cases were selected for testing. The level of geographic stratification in the sampling process did not meaningfully affect accuracy estimates. These findings can inform testing thresholds for laboratory surveillance programs in the meningitis belt.

Indexed as

AfricaHumansMeningitis, BacterialPopulation SurveillancePublic Health SurveillanceBacterial MeningitisBurkina FasoChadLaboratory SurveillanceMaliModelingNigerTogo

Identifiers

PMID34469549
PMCPMC8409536
OpenAlexW3196582933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.